MREO Mereo Biopharma Group Plc
- Stocks
- Healthcare
- NASDAQ: MREO
Price (delayed)
$1.8
Market cap
$286.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.35
Enterprise value
$230.85M
Relative Growth:
Rel. Growth:
3
Relative Strength:
Rel. Strength:
16
Relative Valuation:
Rel. Valuation:
1
Relative Profitability:
Rel. Profitability:
16
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate,
Highlights
Mereo Biopharma Group's debt has shrunk by 90% YoY and by 20% QoQ
The quick ratio has grown by 32% YoY but it has contracted by 11% from the previous quarter
The gross profit has plunged by 76% YoY
The gross margin has plunged by 51% YoY
Key stats
What are the main financial stats of MREO
Market
Valuations
Earnings
Shares outstanding
159.1M
Market cap
$286.37M
Enterprise value
$230.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.28
Price to sales (P/S)
575.59
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
461.7
Revenue
$500,000
Gross profit
$368,000
Operating income
-$46.35M
Net income
-$49.55M
EBIT
-$50.35M
EBITDA
-$49.23M
Free cash flow
-$32.94M
Per share
Balance sheet
Liquidity
EPS
-$0.35
EPS diluted
-$0.35
Free cash flow per share
-$0.21
Book value per share
$0.34
Revenue per share
$0
TBVPS
$0.39
Total assets
$62.63M
Total liabilities
$8.45M
Debt
$601,000
Equity
$54.18M
Working capital
$53.86M
Debt to equity
0.01
Current ratio
8.13
Quick ratio
7.43
Net debt/EBITDA
1.13
Margins
Efficiency
Dividend
EBITDA margin
-9,845.2%
Gross margin
73.6%
Net margin
-9,910%
Operating margin
-9,269.8%
Return on assets
-66.9%
Return on equity
-80%
Return on invested capital
N/A
Return on capital employed
-91.4%
Return on sales
-10,070%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MREO stock price
How has the Mereo Biopharma Group stock price performed over time
Intraday
1.12%
1 week
-6.25%
1 month
-11.76%
1 year
-56.1%
YTD
-48.57%
QTD
-12.62%
Financial performance
How have Mereo Biopharma Group's revenue and profit performed over time
Revenue
$500,000
Gross profit
$368,000
Operating income
-$46.35M
Net income
-$49.55M
Gross margin
73.6%
Net margin
-9,910%
Mereo Biopharma Group's net margin has shrunk by 169% YoY
Mereo Biopharma Group's operating margin has shrunk by 138% YoY
The gross profit has plunged by 76% YoY
The gross margin has plunged by 51% YoY
Price vs fundamentals
How does MREO's price correlate with its fundamentals
Growth
What is Mereo Biopharma Group's growth rate over time
Valuation
What is Mereo Biopharma Group stock price valuation
P/E
N/A
P/B
5.28
P/S
575.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
461.7
The EPS has contracted by 40% YoY
The P/B is 33% lower than the last 4 quarters average of 7.9
The equity has declined by 31% year-on-year and by 10% since the previous quarter
Mereo Biopharma Group's revenue has shrunk by 50% YoY
Efficiency
How efficient is Mereo Biopharma Group business performance
The ROS has plunged by 174% YoY
MREO's ROA has shrunk by 79% YoY and by 17% QoQ
The return on equity has dropped by 64% year-on-year and by 15% since the previous quarter
Dividends
What is MREO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MREO.
Financial health
How did Mereo Biopharma Group financials performed over time
Mereo Biopharma Group's total liabilities has shrunk by 52% YoY but it has increased by 2.6% QoQ
MREO's total assets is down by 35% year-on-year and by 8% since the previous quarter
Mereo Biopharma Group's debt is 99% lower than its equity
Mereo Biopharma Group's debt has shrunk by 90% YoY and by 20% QoQ
Mereo Biopharma Group's debt to equity has shrunk by 88% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.